Cyted Ltd.. (9/29/20). "Press Release: Cyted Appoints Martin Frost as Commercial and Strategic Advisor". Cambridge.

	Organisation	Cyted Ltd.
	Group	Cyted (Group)
	Organisation 2	CMR Surgical Ltd.
	Product	AI-based diagnostics
	Product 2	artificial intelligence (AI) / machine learning (ML)
	Person	Frost, Martin (CMR Surgical 202009 CEO + Co-Founder)
	Person 2	West, Will (CellCentric –200710– CEO + Morningside Ventures 202109)

CMR Surgical founder and CEO appointed to support rapid commercialisation of artificial intelligence and digital diagnostic products and services

Cyted Ltd (“Cyted” or “the Company”), a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, today announced that it has appointed Martin Frost as Commercial and Strategic Advisor. In this role, Martin will guide the Cyted team as the Company continues to grow and commercialise its products and services offering.

Martin has over 20 years of industry experience, including co-founding CMR Surgical in 2014. As CEO of CMR he was recognised as ‘UK Disruptor of the year’ in the 2019 Entrepreneur of the Year awards, and ‘Executive of the Year’ at the 2019 MedTech Insight awards, recognising his success in taking CMR from inception to global commercialisation with its surgical robot, Versius. To scale CMR, Martin raised over £250m, a record for any private European medical devices business.

Previously Martin has held a number of C-suite positions including CEO and CFO of Sagentia, the leading technology development company based in Cambridge, which he listed on the London Stock Exchange. Martin qualified as a Chartered Management Accountant, graduated from Cambridge University, and is Chair of the Peek Vision Foundation.

Cyted is enabling the earlier detection of disease, providing products and services that combine proprietary artificial intelligence technology and digital diagnostic infrastructure with next generation biomarkers. With significant expertise in pathology, the Company is developing a pipeline of digital and molecular tests for disease detection and risk stratification, to streamline diagnostic and clinical workflows. Cyted is initially focused on oesophageal cancer, where the combination of an identifiable at-risk population coupled with excellent therapy options offers a unique opportunity to improve patient outcomes through early detection.

Dr Will West, Chairman, Cyted, said: “Martin is a recognised commercial leader in successfully scaling technology and life science businesses. To have him involved at this stage of Cyted’s development is fantastic, as we embark on the next phase towards commercialisation.”

Martin Frost, Commercial and Strategic Advisor, Cyted, said: “What the team at Cyted has already achieved in terms of technical developments is impressive, and I look forward to working with Marcel and the Company as we continue to build strategic partnerships and move towards the commercialisation of Cyted’s products and services.”

Marcel Gehrung, CEO of Cyted, said: “Martin has an exceptional track record in the biotech, medtech and medical device development sectors and it is a privilege to welcome him to the team. With Martin’s help we plan to focus on the development of partnerships with NHS trusts, academic health networks and commercial groups, as well as continuing to expand the team at all levels.”

For additional information please visit https://cyted.ai

ENDS

Notes to editors

Image: Martin Frost, Cyted Commercial and Strategic Advisor
For a high-resolution image please contact Zyme Communications

Media contact:

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About Cyted https://cyted.ai

Cyted is enabling the earlier detection of disease, providing products and services that combine proprietary artificial intelligence technology and digital diagnostic infrastructure with next generation biomarkers.

With significant expertise in pathology, the Company is developing a pipeline of digital and molecular tests for disease detection and risk stratification to streamline diagnostic and clinical workflows. Cyted has the capacity to rapidly implement its sample processing and analysis workflow at scale via Dialogical®, its proprietary pathology reporting platform based on machine learning algorithms.

The Company’s services and products are initially focused on oesophageal cancer, where the combination of patient population, pathological analysis and therapeutic options offers a unique opportunity to improve patient outcomes through early detection.

Cyted is headquartered in Cambridge, UK. For more information, visit cyted.ai

Record changed: 2023-06-05